FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1548-1557 November 22, 2001 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Fenoldopam mesylate, a benzazepine derivative, is the first selective dopamine-1–receptor agonist that has been approved for clinical use. Administered parenterally, it acts predominantly as a vasodilator in peripheral arteries and as a diuretic in the kidneys. It has been approved by the U.S. Food and Drug Administration for the in-hospital, short-term (up to 48 hours) management of severe hypertension, when rapid but quickly reversible reduction of blood pressure is required, including malignant hypertension with deteriorating end-organ function. In this review, we examine the development of fenoldopam, its pharmacologic characteristics, and its clinical efficacy.

Severe hypertension is common, although its prevalence . . . [Full Text of this Article]

From Dopamine to an Antihypertensive Drug

Dopamine Receptors

Pharmacology of Fenoldopam

Pharmacokinetics

Antihypertensive Actions of Fenoldopam

Oral Fenoldopam in Mild-to-Moderate Hypertension

Intravenous Fenoldopam in Mild-to-Moderate Hypertension

Intravenous Fenoldopam in Severe Hypertension

Intravenous Fenoldopam in Hypertensive Emergencies

Fenoldopam for Hypertension during the Perioperative Period

Adverse Effects

Drug–Drug Interactions

Fenoldopam as a Renal Protective Drug

Indications for Fenoldopam Therapy

Conclusions

Source Information

From the Departments of Pharmacology and Therapeutics (M.B.M.) and the Departments of Anesthesia and Intensive Care Medicine (C.M., G.D.S.), University College Cork, Cork, Ireland.

Address reprint requests to Dr. Murphy at the Department of Pharmacology and Therapeutics, Clinical Sciences Bldg., Cork University Hospital, Wilton, Cork, Ireland, or at mmurphy@medicine.ucc.ie.

References

This article has been cited by other articles:

• Rhoney, D., Peacock, W. F. (2009). Intravenous therapy for hypertensive emergencies, part 1. Am J Health Syst Pharm 66: 1343-1352 [Abstract] [Full Text]  
• Zhang, M.-Z., Yao, B., Fang, X., Wang, S., Smith, J. P., Harris, R. C. (2009). Intrarenal Dopaminergic System Regulates Renin Expression. Hypertension 53: 564-570 [Abstract] [Full Text]  
• Ricci, Z., Stazi, G. V., Di Chiara, L., Morelli, S., Vitale, V., Giorni, C., Ronco, C., Picardo, S. (2008). Fenoldopam in newborn patients undergoing cardiopulmonary bypass: controlled clinical trial. ICVTS 7: 1049-1053 [Abstract] [Full Text]  
• Staessen, J. A., Kuznetsova, T., Zhang, H., Maillard, M., Bochud, M., Hasenkamp, S., Westerkamp, J., Richart, T., Thijs, L., Li, X., Brand-Herrmann, S.-M., Burnier, M., Brand, E. (2008). Blood Pressure and Renal Sodium Handling in Relation to Genetic Variation in the DRD1 Promoter and GRK4. Hypertension 51: 1643-1650 [Abstract] [Full Text]  
• Zeng, C., Armando, I., Luo, Y., Eisner, G. M., Felder, R. A., Jose, P. A. (2008). Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. Am. J. Physiol. Heart Circ. Physiol. 294: H551-H569 [Abstract] [Full Text]  
• Skov, K., Eiskjaer, H., Hansen, H. E., Madsen, J. K., Kvist, S., Mulvany, M. J. (2007). Treatment of Young Subjects at High Familial Risk of Future Hypertension With an Angiotensin-Receptor Blocker. Hypertension 50: 89-95 [Abstract] [Full Text]  
• Bacic, D., Capuano, P., Baum, M., Zhang, J., Stange, G., Biber, J., Kaissling, B., Moe, O. W., Wagner, C. A., Murer, H. (2005). Activation of dopamine D1-like receptors induces acute internalization of the renal Na+/phosphate cotransporter NaPi-IIa in mouse kidney and OK cells. Am. J. Physiol. Renal Physiol. 288: F740-F747 [Abstract] [Full Text]  
• Zeng, C., Sanada, H., Watanabe, H., Eisner, G. M., Felder, R. A., Jose, P. A. (2004). Functional genomics of the dopaminergic system in hypertension. Physiol. Genomics 19: 233-246 [Abstract] [Full Text]  
• Briguori, C., Colombo, A., Airoldi, F., Violante, A., Castelli, A., Balestrieri, P., Paolo Elia, P., Golia, B., Lepore, S., Riviezzo, G., Scarpato, P., Librera, M., Focaccio, A., Ricciardelli, B. (2004). N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 44: 762-765 [Abstract] [Full Text]  
• Devlin, J. W, Seta, M. L, Kanji, S., Somerville, A. L (2004). Fenoldopam Versus Nitroprusside for the Treatment of Hypertensive Emergency. The Annals of Pharmacotherapy 38: 755-759 [Abstract] [Full Text]  
• Zeng, C., Wang, D., Yang, Z., Wang, Z., Asico, L. D., Wilcox, C. S., Eisner, G. M., Welch, W. J., Felder, R. A., Jose, P. A. (2004). Dopamine D1 Receptor Augmentation of D3 Receptor Action in Rat Aortic or Mesenteric Vascular Smooth Muscles. Hypertension 43: 673-679 [Abstract] [Full Text]  
• Guzman, J. A., Rosado, A. E., Kruse, J. A. (2003). Dopamine-1 receptor stimulation impairs intestinal oxygen utilization during critical hypoperfusion. Am. J. Physiol. Heart Circ. Physiol. 284: H668-H675 [Abstract] [Full Text]